Lanreotide
Lanreotide (Somatuline Depot)
Get Lanreotide
Sourced from Ascension Peptides. Verified ≥Pharmaceutical grade purity, third-party tested. COA included.
Off with code
PEPTIDEDECK
Table of Contents
What is Lanreotide?
Lanreotide is a synthetic somatostatin analog, a laboratory-made peptide that reproduces the inhibitory actions of the natural hormone somatostatin. Somatostatin is produced throughout the body and acts as a broad off-switch, suppressing the secretion of growth hormone from the pituitary and of many hormones from the pancreas and digestive tract. Because native somatostatin lasts only minutes in the bloodstream, analogs like lanreotide were developed to deliver the same suppressive effects with a far longer duration.
Lanreotide is a cyclic octapeptide, meaning eight amino acids joined in a ring closed by a disulfide bridge. This compact, stabilized structure resists enzymatic breakdown and preferentially engages somatostatin receptor subtypes 2 and 5, the subtypes most relevant to controlling growth hormone and neuroendocrine tumor activity. Marketed as Somatuline Depot, it is one of two dominant somatostatin analogs in clinical use, the other being octreotide.
Lanreotide is approved to treat two main conditions: acromegaly, a disorder of growth hormone excess usually caused by a pituitary tumor, and gastroenteropancreatic neuroendocrine tumors, which are hormone-producing tumors of the digestive system and pancreas. In both settings, lanreotide serves to reduce excess hormone secretion, control symptoms, and, in the case of neuroendocrine tumors, slow tumor growth. Its combination of broad hormonal suppression and convenient long-acting delivery makes lanreotide a cornerstone therapy in endocrine oncology.
Research Benefits
Suppresses growth hormone in acromegaly
Controls symptoms of neuroendocrine tumors
Slows tumor progression (CLARINET data)
Self-injectable depot formulation
Once-monthly dosing convenience
Reduces hormone secretion from NETs
Well-established long-term safety
Comparable efficacy to octreotide
How Lanreotide Works
Lanreotide works by binding to somatostatin receptors on target cells and switching off the secretion of hormones those cells would otherwise release. Somatostatin receptors are G-protein coupled receptors that, when activated, suppress the intracellular signals that drive hormone production and secretion, and in some tumor cells they also restrain cell growth.
Receptor Selectivity
Lanreotide binds with highest affinity to somatostatin receptor subtype 2 and, to a lesser degree, subtype 5. This selectivity is clinically important because subtype 2 mediates much of the suppression of growth hormone and the control of neuroendocrine tumor secretion. By concentrating its action on these receptors, lanreotide achieves strong therapeutic effects on the conditions it treats.
Growth Hormone Suppression
Inhibits pituitary growth hormone release, lowering the excess that drives acromegaly.
Hormone Secretion Control
Reduces secretion of gut and pancreatic hormones responsible for neuroendocrine tumor symptoms.
Antiproliferative Action
Restrains growth of certain neuroendocrine tumors, slowing disease progression.
Gut Hormone Inhibition
Lowers gastrin, secretin, and related hormones, easing symptoms like flushing and diarrhea.
Controlling Growth Hormone in Acromegaly
Lanreotide reduces the elevated growth hormone and, consequently, the high insulin-like growth factor 1 levels that characterize acromegaly. Lowering these hormones eases the symptoms of the disease and can shrink or stabilize the underlying pituitary tumor in some patients. Because somatostatin naturally opposes growth hormone release, a long-acting somatostatin analog is a logical and effective treatment for growth hormone excess.
Antiproliferative Effects in Neuroendocrine Tumors
Lanreotide does more than control symptoms in neuroendocrine tumors; it can slow the tumors themselves. Activation of somatostatin receptors on tumor cells suppresses growth-promoting signals and can trigger cell cycle arrest. This antiproliferative action underlies lanreotide's role as a disease-modifying therapy, extending the time before certain neuroendocrine tumors progress, not merely masking their hormonal symptoms.
Research Applications
Acromegaly treatment
Active research area with published studies
Gastroenteropancreatic neuroendocrine tumors
Active research area with published studies
Carcinoid syndrome
Active research area with published studies
Tumor antiproliferative effects
Active research area with published studies
Polycystic kidney and liver disease
Active research area with published studies
Dumping syndrome
Active research area with published studies
Quality of life optimization
Active research area with published studies
Long-term disease management
Active research area with published studies
Research Findings
Lanreotide is supported by a substantial body of clinical research establishing its efficacy in acromegaly and neuroendocrine tumors, including landmark evidence for its ability to slow tumor progression.
The CLARINET Trial
Lanreotide's antiproliferative benefit was established in the CLARINET trial, which studied people with non-functioning enteropancreatic neuroendocrine tumors. The trial found that lanreotide significantly prolonged the time before tumors progressed compared with placebo, providing strong evidence that the drug slows disease, not just symptoms. This finding elevated lanreotide from a symptom-control agent to a recognized disease-modifying treatment in neuroendocrine tumor care.
🔑 Key Clinical Findings
- The CLARINET trial showed lanreotide slows progression of certain neuroendocrine tumors
- Lanreotide effectively lowers growth hormone and IGF-1 in acromegaly
- It controls carcinoid syndrome symptoms such as flushing and diarrhea
- Efficacy is broadly comparable to octreotide, with formulation as the main practical difference
- The self-injectable depot improves convenience and quality of life over facility-administered options
Acromegaly Control
Lanreotide research in acromegaly demonstrates consistent reductions in growth hormone and insulin-like growth factor 1, with many patients achieving biochemical control. Long-term studies show durable suppression with monthly dosing and, in some cases, reduction in pituitary tumor size. These results make lanreotide a mainstay medical therapy for acromegaly, used when surgery is not curative or not appropriate.
| Compound | Class | Formulation | Typical Dosing |
|---|---|---|---|
| Native somatostatin | Natural hormone | Not practical | Minutes of activity |
| Octreotide LAR | Somatostatin analog | Long-acting depot | Monthly, facility-given |
| Lanreotide | Somatostatin analog | Self-injectable depot | Monthly, home or clinic |
Comparative Research
Lanreotide and octreotide have been compared extensively, and research generally shows similar efficacy for controlling hormone excess and neuroendocrine tumor symptoms. The meaningful distinctions tend to be practical: the lanreotide depot can be administered at home, while some octreotide formulations require reconstitution and clinic administration. Individual patients may also respond or tolerate one agent better than the other, so the choice is often guided by convenience and response.
Dosage & Administration
Lanreotide is a prescription medication, and the dosing information below describes clinical use for context, not as personal medical instruction. Any use of lanreotide should be prescribed and monitored by a qualified healthcare provider.
Formulation and Route
Lanreotide is supplied as a ready-to-use depot in a pre-filled syringe and is given by deep subcutaneous injection, typically into the upper outer area of the buttock. Once injected, the supersaturated formulation forms a depot that releases the drug slowly over about a month, which is why a single injection provides sustained hormone suppression.
Standard Dose Range
Lanreotide depot is available in strengths of 60, 90, and 120 milligrams, and the dose is individualized based on the condition treated and the patient's biochemical and symptom response. Treatment is often started at an intermediate dose and adjusted at follow-up based on hormone levels and symptom control.
| Indication | Approach | Adjustment Basis |
|---|---|---|
| Acromegaly | Monthly depot, dose individualized | Growth hormone and IGF-1 levels |
| Neuroendocrine tumors | Higher-strength monthly depot common | Symptom control and tumor status |
| Carcinoid syndrome | Monthly depot | Flushing and diarrhea frequency |
Administration Practices
Allow to Reach Room Temperature
The pre-filled syringe is typically brought to room temperature before injection for comfort and flow.
Deep Subcutaneous Injection
The depot is placed deep in the subcutaneous tissue, usually in the upper outer buttock, alternating sides each month.
Maintain the Monthly Schedule
Consistent monthly timing keeps hormone suppression steady between doses.
Store Refrigerated
Lanreotide depot is kept refrigerated and protected from light until use.
Practical Insight
Because lanreotide controls a chronic condition over many years, adherence to the monthly schedule and periodic checks of hormone levels, gallbladder health, and glucose are central to safe long-term therapy.
Safety & Side Effects
Lanreotide has a well-characterized safety profile from long clinical use. Because it broadly suppresses digestive and pancreatic function, most of its side effects relate to the gastrointestinal system and the gallbladder.
Common Side Effects
Lanreotide most often produces gastrointestinal effects, reflecting its inhibition of gut motility and pancreatic secretion.
Diarrhea and Abdominal Pain
Common early effects, often improving over the first months of treatment.
Gallstones and Biliary Sludge
Reduced gallbladder emptying promotes gallstone formation, a recognized class effect.
Glucose Changes
Suppression of insulin and glucagon can shift blood glucose up or down, requiring monitoring.
Injection Site Reactions
Local nodules, pain, or redness at the depot injection site, usually mild.
Important Safety Considerations
Lanreotide carries several considerations tied to its broad inhibitory action:
- Gallbladder disease: Long-term therapy increases the risk of gallstones due to reduced gallbladder contraction, so periodic imaging is common
- Glucose regulation: Because both insulin and glucagon are suppressed, glucose can rise or fall, and people with diabetes require closer monitoring
- Fat malabsorption: Reduced pancreatic enzyme secretion can cause fatty, loose stools, a manifestation of impaired fat digestion
- Heart rate: Somatostatin analogs can slow heart rate, a consideration in people with underlying bradycardia or cardiac conduction issues
- Thyroid and pituitary function: Long-term suppression can affect other hormone axes, warranting periodic evaluation
Monitoring
Lanreotide therapy is monitored with periodic gallbladder ultrasound, blood glucose checks, and measurement of the relevant hormone levels such as growth hormone and IGF-1 in acromegaly. Dose and interval are adjusted based on how well hormone excess and symptoms are controlled, balanced against tolerability.